key: cord-0855096-vj6ux7a9
authors: Kaul, Malvika; Gupta, Preeti; Kalra, Salil; Gardner, Jessica; Gordon, Howard S.; Rubinstein, Israel
title: New domiciliary supplemental oxygen therapy after hospitalization for COVID-19 in metropolitan Chicago
date: 2022-02-24
journal: ERJ Open Res
DOI: 10.1183/23120541.00577-2021
sha: dc0d598f2fcb87bddbea7a2fe851fc45f71a3ae2
doc_id: 855096
cord_uid: vj6ux7a9

BACKGROUND: A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of COVID-19 hospitalisations with persistent hypoxemia upon discharge. The purpose of this single center study was to begin to address this issue. METHODS: In this retrospective study we report features of U.S. military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO, and were followed for 6 months. RESULTS: We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and discharged on DSO did not undergo a formal 6-min walk test (6 MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Blacks in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%). CONCLUSIONS: Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6 MWT, of patients who survived COVID-19 hospitalisations and treated with DSO for persistent hypoxemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies.

It is well-established that long-term, domiciliary supplemental oxygen therapy is beneficial in some patients with distinct lung diseases (1) (2) (3) (4) (5) . To that end, a knowledge gap exists in understanding the attributes of domiciliary supplemental oxygen therapy among survivors of COVID-19 hospitalizations who were discharged with domiciliary supplemental oxygen therapy due to persistent hypoxemia (6) (7) (8) (9) .

For instance, Chopra et al (10) reported that only 32 out of 1,250 survivors of COVID-19 hospitalizations in the State of Michigan (2.6%) required new domiciliary supplemental oxygen 60 days after discharge. Banerjee et al (11) found low 30-day allcause mortality (1.3%) and hospital re-admission rate (8.5%) among 621 patients with acute COVID-19 illness in the U.S. who were discharged from the hospital with supplemental oxygen. However, the median follow-up of these patients was only 26 days thereby precluding assessment of long-term, domiciliary supplemental oxygen therapy. Moreover, whether these patients had new supplemental oxygen requirements upon hospital discharge was not addressed in this study. Finally, Shah et al (7) did not report new supplemental oxygen requirements among 60 patients prospectively followed for 12 weeks for respiratory outcomes after COVID-19 hospitalizations in Vancouver, Canada.

Given the paucity of studies addressing clinical management of new domiciliary supplemental oxygen therapy among survivors of COVID-19 hospitalizations with persistent hypoxemia, the purpose of this single center, retrospective study was to begin to address this knowledge gap. Here we report features of U.S. military veterans residing in metropolitan Chicago with no prior domiciliary supplemental oxygen therapy who survived COVID-19 hospitalizations, were discharged with domiciliary supplemental oxygen therapy due to persistent hypoxemia and were followed for 6 months. Patient data abstracted from CPRS comprised of demographics, co-morbidities, and hospital course. After hospital discharge, data collected from CPRS included flow rate and duration of domiciliary supplemental oxygen therapy, follow-up virtual and/or face-to-face clinic visits with healthcare providers, unscheduled visits to the emergency department, hospitalizations, and documentation of post-acute sequelae of SARS-CoV-2 infection (PASC) symptoms (defined below) by health care providers at day 30, week 8, and from 8 weeks to 6 months thereafter. In each patient, the need for domiciliary supplemental oxygen upon hospital discharge was assessed by detailed medical history, clinical examination, and pulse oximetry <88% at rest or during ambulation. Domiciliary supplemental oxygen, ancillary equipment, technical support, education, educational resources, and regular home visits were provided to eligible patients by a single commercial vendor contracted by JBVAMC in accordance with Veterans Health Administration Directive 1173.13. Post-acute sequelae of SARS-CoV-2 infection was defined as symptoms and/or abnormalities associated with SARS-CoV-2 infection (e.g., "brain fog" and shortness of breath) that persisted beyond 4 weeks of hospital discharge that were not present prior to the onset of SARS-CoV-2 and were not attributable to alternative diagnoses (12) (13) (14) (15) (16) .

Descriptive statistics were used for primary analysis and are reported as means and standard deviation, median with interquartile range (IQR) and percent where appropriate.

We found that 65 of 285 patients (23%) with acute COVID-19 illness were discharged from JBVAMC with new domiciliary supplemental oxygen therapy during the study period. None had domiciliary supplemental oxygen therapy prescribed before contracting COVID-19 infection. Patient characteristics are depicted in Table 1 . They were elderly (median age, 70), obese, predominantly Black (69%) men (94%) ( Table 1) .

Sixty-eight per cent had a history of smoking and 19% reported smoking tobacco at the time of hospital admission. The predominant underlying co-morbidities among this cohort were hypertension (83%), hyperlipidemia (62%), diabetes mellitus type-2 (49%), obstructive sleep apnea (40%), chronic obstructive pulmonary disease (COPD) (29%), and gastroesophageal reflux disease (25%) ( Table 1) .

During hospitalization, 2 patients (3%) required invasive mechanical ventilation, 7 (10%) non-invasive ventilation, and 19 (29%) high-flow supplemental oxygen delivered with nasal cannulae. The remaining 37 patients required supplemental oxygen at flow rates ≤5 L/min or none. Mean length of hospital stay was 11±10 days. All 65 patients were discharged from JBVAMC with a median supplement oxygen flow rate of 2 L/min (IQR, 2-2 L/min) either continually or during exertion (Table 1) .

All 65 patients were followed for 6 months after hospital discharge. Within 30 days of hospital discharge, 50 patients (77%) had at least one follow-up clinic virtual pr face-to-face visit with a primary care physician (PCP) at JBVAMC. Eighteen patients (28%) had at least one unscheduled visit to the emergency department and 9 (14%) had at least one all-cause readmission to JBVAMC. No deaths were reported during this time frame (Table 2) .

Eight weeks after hospital discharge, 60 patients (92%) had at least one followup virtual or face-to-face clinic visit with a PCP at JBVAMC. Twenty-three patients (35%) had at least one unscheduled visit to the emergency department and 13 (20%) had at least one all-cause hospitalization at JBVAMC during this time frame. Importantly, 43 patients (66%) reported PASC (Table 2) . No deaths were reported during this observation period. (Table 2) . Two patients (3%) died during follow-up, both did not require high flow nasal cannula or non-invasive or invasive ventilation during their index hospitalization. (Table 2) .

A six-minute walk test (6MWT) to assess ongoing requirement for domiciliary supplemental oxygen therapy was only performed in 4 patients prior to 8 weeks and 15 patients (23%) after 8 weeks from hospital discharge. Nonetheless, domiciliary supplemental oxygen therapy was discontinued in 34 patients (52%) within 8 weeks of hospital discharge ( Table 2 ), 6 of which had discontinuation of supplemental oxygen within 4 weeks of discharge. The number of patient referrals to the pulmonary clinic at JBVAMC during the 6-month observation period was less than 50% during each study period. (Table 2) .

Thirty patients (46%), predominantly obese Black males with hypertension and hyperlipidemia, who were discharge with domiciliary supplemental oxygen therapy reported PASC for at least 8 weeks after hospital discharge reported PASC ( Table 3) .

Out of these only 10 patients (33%) had documented supplemental oxygen discontinued by self or provider during the study period (from 4 weeks to 6 months of index COVID-19 hospitalization). None required invasive mechanical ventilation during hospitalization. Thirteen patients required supplemental high-flow oxygen therapy through nasal cannula or noninvasive ventilation. Nine patients (30%) were re-admitted to JBVAMC within 30 days of hospital discharge while 10 (33%) were re-admitted within subsequently diagnosed with PASC died during follow-up (Table 3) .

There are three new findings of this study. We found that the majority of elderly patients, predominantly obese Black males, residing in metropolitan Chicago who survived COVID-19 hospitalizations at JBVAMC, discharged on domiciliary supplemental oxygen due to persistent hypoxemia, and followed for 6 months did not undergo 6MWT to re-assess the need for domiciliary supplemental oxygen. The limitations of our retrospective study are obvious, including single medical center in metropolitan Chicago, small sample size, male predominance, and no matched control group. This limits the generalizability of our observations and limit our ability to elucidate the possible roles of comorbid conditions and tobacco smoking as risk factors for developing PASC. We also recognize that most outpatient encounters reported in this study occurred remotely using telehealth-enabled technology due to the ongoing COVID-19 pandemic in metropolitan Chicago. This may have limited formal health assessment, including ongoing need for supplemental oxygen, of our patients.

Nonetheless, we have addressed this issue, in part, by extending the study period to 6 months after hospital discharge thereby facilitating patient access to primary care providers at JBVAMC. In addition, interrogation of CPRS, JBVAMC-specific robust electronic health record, enabled us to capture all post-discharge clinic and virtual visits of our patients along with complications observed during this time frame. Moreover, the commercial vendor contracted by JBVAMC provided regular delivery of oxygen tanks or concentrators and supplies along with home visits to patients' residences thereby promoting adherence with prescribed supplemental oxygen therapy.

Finally, the results of this study underscore the need to develop, implement and disseminate cost-effective, wireless, telehealth-enabled technologies to monitor patients who survived COVID-19 hospitalizations with limited access to clinic visits after discharge for actual need for domiciliary supplemental oxygen therapy.

In summary, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who 

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial

A randomized trial of long-term oxygen for COPD with moderate desaturation

Optimizing home oxygen therapy

Home oxygen in chronic obstructive pulmonary disease

Home oxygen therapy for adults with chronic lung disease. An official

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations

COVID-19 discharge and follow-up recommendations

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Sixty-day outcomes among patients hospitalized with COVID-19

Mortality and readmission rates among patients with COVID-19 after discharge from acute care setting with supplemental oxygen

World Health Organization. A clinical case definition of post-COVID-19 condition by a Delphi consensus

High-dimensional characterization of post-acute sequelae of COVID-19

Population-based estimates of postacute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics

Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study

Short-term home oxygen therapy for COVID-19 patients: the COVID-HOT algorithm

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Post-discharge health status and symptoms in patients with severe COVID-19

Discharge characteristics and care transitions of hospitalized patients with COVID-19

This work was supported, in part, by grants I50 CU000179-01 (IR) and IIR 12- None of the authors has declared any conflict of interest which may arise from being named as an author of this manuscript.